Stock Evaluator: Zai Lab Limited (ZLAB)

Zai Lab Limited ZLAB

$18.27 0.06 0.33%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 353,712
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Commentary & Analysis


Financial Summary

Share Statistics ZLAB Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $2,046.0 $251.9 54%
Shares Out (Mil) 110.7 50.8 64%
Institutional Ownership 95.8% 92.0% 68%
Float (Mil) 91.7 40.5 60%
Beta 0.84 0.95 50%
Avg Daily Volume (000s) 631 447 63%
Price Change
(52-week)
(55.1%) 54.2% 14%
Growth ZLAB Industry
Median
Percentile
(All Stocks)
Sales (5yr) 56.5% 14.0% 97%
Net Income (5yr) 8.2% (9.8%) 52%
EPS (5yr) 14.3% 16.3% 54
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.0%) (15.6%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 6 10 10
Current EPS ($0.679) ($2.195) ($1.758)
Month Ago EPS ($0.061) ($0.210) ($0.202)
# Rev Up 0 1 1
# Rev Down 2 0 0
Three Months Ago EPS ($0.045) ($0.454) ($0.408)
Year/Year Chg 47.3% 36.9% (40.5%)
Financials ZLAB Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $453 $39 40%
Net Income (TTM) (Mil) ($178) ($43) 7%
EPS (TTM) ($1.616) ($1.600) 17%
Operating Cash Flow (TTM) (Mil) ($101) ($30) 6%
Net Cash Flow (TTM) (Mil) ($106) $3 14%
Long-Term Debt (Q1) (Mil) $12 $5 29%
Enterprise Value (Q1) (Mil) $1,662 $182 47%
Valuation ZLAB Industry
Median
Percentile
(All Stocks)
P/B 3.06 2.60 66%
P/E na 18.6 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios ZLAB Industry
Median
Percentile
(All Stocks)
Gross Margin 8.1% 63.8% 8%
Net Margin (39.3%) (64.7%) 13%
ROA (15.7%) (49.7%) 22%
ROE (24.2%) (55.4%) 22%
Liabilities to Assets 39.6% 30.3% 30%
F-Score 5 3 51%

Zai Lab Limited did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors